High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin

Journal of Thoracic Oncology

Volumn 4, Issue 7, 2009, Pages 845-852

  Arrieta, Oscar ^a,b   Rincón, Dolores Gallardo ^a   Garza, Cynthia Villarreal ^a   Michel, Rosa M ^a   Ramos, Alma M Astorga ^b   Barrera, Luis Martínez ^c   De La Garza, Jaime ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^c INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Gemcitabine; Induction chemotherapy; NSCLC; Radiation pneumonitis

Indexed keywords

CARBOPLATIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL EVALUATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGITIS; FATIGUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION PNEUMONIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

EID: 68349116963     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181a97e17     Document Type: Article

References (68)

1. Stewart BW, Kleihues P (Eds). World Cancer Report. Lyon, France: IARC Press; 2003.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2002;55:74-108. (Pubitemid 29094960)
3. Pérez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987;59:1874-1881.
4. Vokes EE, Crawford J, Bogart J, Socinski MA, Clamon G, Green MR. Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res 2006;11:5045s-5050s. (Pubitemid 47181378)
5. Auperin A, Le Pechoux C, Pignon JP, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 2006;17:473-483. (Pubitemid 43329586)
6. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon- Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo- Cancerologie NPC 95-01 Study. J Clin Oncol 2006;23:5910-5917. (Pubitemid 46300207)
7. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699. (Pubitemid 29415225)
8. Curran W, Scott CJ, Langer C, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:621 (Abstract 2499).
9. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-smallcell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005;23:5883-5891. (Pubitemid 46300204)
10. Huber RM, Flentje M, Schmidt M, et al.; Bronchial Carcinoma Therapy Group. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 2006;24:4397-4404. (Pubitemid 46630977)
11. Vokes EE, Hemdon JE, Kelley MJ, et al. Induction chemotherapy followed by concomitant chemoradiotherapy versus chemoradiotherapy alone for regionally advanced unresectable non-small cell lung cancer: initial analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 2004;22:14S (Abstract 7005).
12. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel following concurrent chemoradiotherapy in pathologic stage IIIB nonsmall cell lung cancer: S9504, A Southwest Oncology Group Study. J Clin Oncol 2003;21:2004-2010. (Pubitemid 46606390)
13. Davies AM, Chansky K, Lau DH, et al.; SWOG S9712. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol 2006;24:5242-5246. (Pubitemid 46631368)
14. Reboul FL. Radiotherapy and chemotherapy in locally advanced nonsmall cell lung cancer: preclinical and early clinical data. Hematol Oncol Clin North Am 2004;18:41-53. (Pubitemid 38201548)
15. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS. Metabolism of 2', 2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994;54:3218-3223. (Pubitemid 24980049)
16. Lawrence TS, Eisbruch A, McGinn CJ, Fields MT, Shewach DS. Radiosensitization by gemcitabine. Oncology (Williston Park) 1999; 13(Suppl 5):55-60.
17. Milas L, Fujii T, Hunter N, et al. Enhancement of tumor radio response in vivo by gemcitabine. Cancer Res 1999;59:107-114. (Pubitemid 29062965)
18. Mason KA, Milas L, Hunter NR, et al. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Int J Radiat Oncol Biol Phys 1999;44:1125-1135. (Pubitemid 29342915)
19. Mornex F, Girard N. Gemcitabine and radiation therapy in non-smallcell lung cancer: state of the art. Ann Oncol 2006;17:1743-1747. (Pubitemid 44884047)
20. Crino L, Cappuzzo F. Role of gemcitabine in the treatment of advanced non-small cell lung cancer: review of the main phase II and phase III trials. Anticancer Drugs 2001;12(Suppl 3):S9-S13. (Pubitemid 32772477)
21. Langer F, Helsberg K, Schütte WH, Leschinger MI. Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies. Onkologie 2005;28(Suppl 1):1-28. (Pubitemid 44699458)
22. Cardenal F, López-Cabrerizo MP, Antón A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999;1:12-18. (Pubitemid 29022372)
23. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18:122-130. (Pubitemid 30036345)
24. Schiller JH, Harrington D, Belani C, et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
25. Kosmidis PA, Kalofonos HP, Christodoulou C, et al. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 2008;19:115-122.
26. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005;47:69-80. (Pubitemid 39643243)
27. Crino L, Scagliotti GV, Marangolo M, et al. Cisplatin-gemcitabine combination in non-small cell lung cancer. A phase II study. J Clin Oncol 1997;15:297-303. (Pubitemid 27020587)
28. Antón A, Díaz-Fernández N, González Larriba JL, et al. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer 1998;22:139-148. (Pubitemid 29050855)
29. Kosmidis PA, Dimopoulos MA, Syrigos K, et al. Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol 2007;2:135-140. (Pubitemid 47181342)
30. Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 2005;23:8380-8388. (Pubitemid 46260233)
31. Langer CJ, Gandara DR, Calvert P, Edelman MJ, Ozols RF. Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer. Semin Oncol 1999;26(Suppl 4):12-18. (Pubitemid 29166348)
32. Zatloukal P, Petruzelka L, Zemanova M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003;41:321-331. (Pubitemid 36970188)
33. Aguilar-Ponce J, Granados-García M, Villavicencio V, et al. Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 2004;15: 301-306. (Pubitemid 38262632)
34. Dueñas-González A, Cetina-Perez L, Lopez-Graniel C, et al. Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized Phase II study. Int J Radiat Oncol Biol Phys 2005;61:817-823. (Pubitemid 40247977)
35. Manegold C. Gemcitabine (Gemzar) in non-small cell lung cancer. Expert Rev Anticancer Ther 2004;4:345-360. (Pubitemid 38745107)
36. Choy H. Chemoradiation in NSCLC: focus on the role of gemcitabine. Oncology (Williston Park) 2004;18(Suppl 5):38-42.
37. Gonzalez E, Sanchez-Rovira P, Jaen A, et al. Phase I study of concomitant gemcitabine (G) with radiotherapy (RT) in stage III NSCLC. Eur J Cancer 1999;35(Suppl 4):A1054.
38. Zinner R, Fossella F, Komaki R, et al. Phase I trial of concurrent gemcitabine (G) plus chest radiotherapy (XRT), followed by consolidation systemic chemotherapy with G plus cisplatin (CDDP), for patients with stage III and medically inoperable stage II non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999;18:466a (Abstract 1798).
39. Trodella L, Cortesi E, D'Angelillo RM, et al. Concurrent radiochemotherapy with weekly gemcitabine in IIIAN2 non-small cell lung cancer: analysis of an ongoing phase II trial. Proc Am Soc Clin Oncol 2003;22: 675 (Abstract 2713).
40. Albain KS, Swann RS, Rusch VR, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). Proc Am Soc Clin Oncol 2005; (Abstract 7014).
41. Harper P. Update on gemcitabine/carboplatin in patients with advanced non-small cell lung cancer. Semin Oncol 2003;30(Suppl 10):2-12. (Pubitemid 37010797)
42. Cullen M. The development of gemcitabine and carboplatin in the treatment of non-small-cell lung cancer. Lung Cancer 2005;50(Suppl 1):S5-S7. (Pubitemid 41618289)
43. Aerts JG, Surmont V, van Klaveren RJ, et al. A phase II study of induction therapy with carboplatin and gemcitabine among patients with locally advanced non-small cell lung cancer. J Thorac Oncol 2006;1: 532-536. (Pubitemid 47181400)
44. Vokes EE, Herndon JE II, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002;20:4191-4198. (Pubitemid 35191021)
45. Blanco R, Solé J, Montesinos J, et al.; ACROSS. Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: final results of a phase II study. Lung Cancer 2008; 62:62-71.
46. Goor C, Scalliet P, Van Meerbeek J, et al. A phase II study combining gemcitabine and radiotherapy in stage III NSCLC. Proc 21st ESMO Ann Oncol 1996;7(Suppl 5):101a (Abstract).
47. Salinas J, Serna A, de la Fuente I, et al. Gemcitabina como radiosensibilizante en el carcinoma no microcítico de pulmón estadio III. Estudio fase I-II en pacientes con quimioterapia neoadyuvante. Rev Oncol 2001;3(Suppl 1):163 (Abstract).
48. Zajusz A, Zielonka I, Sygula D, et al. Concurrent thoracic radiotherapy and weekly gemcitabine in an advanced non-small cell lung cancer. Radiother Oncol 2000;56(Suppl 1):S66 (Abstract).
49. Athanasiou E, Cyrgias G, Boinis K, et al. Concurrent chemoradiotherapy with gemcitabine for locally advanced non-small cell lung cancer: preliminary results of a phase II study. Proc 23rd ESMO Ann Oncol 1998;9:468a (Abstract).
50. Blackstock AW, Lesser GJ, Fletcher-Steede J, et al. Phase I study of twice w weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001;51:1281-1289. (Pubitemid 33116322)
51. Trodella L, Granone P, Valente S, et al. Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non small-cell lung cancer. J Clin Oncol 2002;20:804-810. (Pubitemid 34111389)
52. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008;26: 2457-2463.
53. Van Putten JW, Price A, van der Leest AH, Gregor A, Little FA, Groen HJ. A Phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 2003;9:2472-2477. (Pubitemid 36842086)
54. Burmeister BH, Fielding DI, Ramsay JR, Baumann KC, Dauth M, Walpole ET. A Phase I study of moderate-dose radiation therapy and weekly gemcitabine in patients with locally advanced non-small cell lung cancer not suitable for radical chemoradiation therapy. Clin Oncol 2005;17:332-336. (Pubitemid 40932105)
55. Scalliet P, Goor C, Galdermans D, et al. Gemzar® (gemcitabine) with thoracic radiotherapy-a phase II pilot study in chemonaive patients with advanced non small cell lung cancer. Proc Am Soc Clin Oncol 1998;17:499a (Abstract 1923).
56. Barlési F, Villani P, Doddoli C, Gimenez C, Kleisbauer JP. Gemcitabine- induced severe pulmonary toxicity. Fundam Clin Pharmacol 2004; 18:85-91. (Pubitemid 38200923)
57. Schwarte S, Wagner K, Karstens JH, Bremer M. Radiation recall pneumonitis induced by gemcitabine. Strahlenther Onkol 2007;183: 215-217. (Pubitemid 46570762)
58. Jeter MD, Jänne PA, Brooks S, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002;53:394-400. (Pubitemid 34525102)
59. Mok T, Zhang L, Liao M, et al. Risk of severe radiation pneumonitis in gemcitabine (GEM) based consolidation chemotherapy after concurrent chemo-radiation (C-RT) in stage III non-small cell lung cancer (NSCLC). J Clin Oncol 2006. ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June 20 Supplement), 2006:17079 (Abstract).
60. Chang HJ, Lee KE, Choi MY, et al. Risk factors of radiation pneumonitis in lung cancer. J Clin Oncol 2008;26 (Abstract 7573).
61. Mehta VK. Predicting and reducing risk of radiation pneumonitis in patients with non small cell lung cancer: a literature review. J Clin Oncol 2005. ASCO Annual Meeting Proceedings. Vol. 23, No. 16S, Part I of II (June 1 Supplement), 2005:7344 (Abstract).
62. Robnett TJ, Machtay M, Vines EF, McKenna MG, Algazy KM, McKenna WG. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 2000;48:89-94. (Pubitemid 30488217)
63. Piotrowski T, Matecka-Nowak M, Milecki P. Prediction of radiation pneumonitis: dose-volume histogram analysis in 62 patients with nonsmall cell lung cancer after three-dimensional conformal radiotherapy. Neoplasma 2005;52:56-62. (Pubitemid 40327528)
64. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323-329. (Pubitemid 29408545)
65. Madani I, De Ruyck K, Goeminne H, De Neve W, Thierens H, Van Meerbeeck J. Predicting risk of radiation-induced lung injury. J Thorac Oncol 2007;2:864-874. (Pubitemid 47361031)
66. Fossella FV, Zinner RG, Komaki R, et al. Gemcitabine with concurrent chest radiation followed by consolidation gemcitabine plus cisplatin: a phase I trial for patients with stage III non small cell lung cancer (NSCLC). Eur J Cancer 2001;37(Suppl 6):S53-S54.
67. Gregor A, Price A, van der Leest AH, et al. Phase I study of gemcitabine and radiotherapy in stage III non-small cell lung cancer. Proc Am Soc Clin Oncol 1999;18:1953a (Abstract).
68. Zinner RG, Komaki R, Cox JD, et al. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-smallcell lung cancer. Int J Radiat Oncol Biol Phys 2009;73:119-127.